Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib

This publication has 29 references indexed in Scilit:

• Sunitinib: From Rational Design to Clinical Efficacy
  Journal of Clinical Oncology, 2007
• Approval Summary: Sunitinib for the Treatment of Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors and Advanced Renal Cell Carcinoma
  Clinical Cancer Research, 2007
• Hypothyroidism in Patients With Metastatic Renal Cell Carcinoma Treated With Sunitinib
  JNCI Journal of the National Cancer Institute, 2007
• Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors in Clinical Trials: Current Status and Future Directions
  The Oncologist, 2006
• Angiogenesis Inhibitors and Hypertension: An Emerging Issue
  Journal of Clinical Oncology, 2006
• Activity of SU11248, a Multitargeted Inhibitor of Vascular Endothelial Growth Factor Receptor and Platelet-Derived Growth Factor Receptor, in Patients With Metastatic Renal Cell Carcinoma
  Journal of Clinical Oncology, 2006
• ACC/AHA 2005 Guideline Update for the Diagnosis and Management of Chronic Heart Failure in the Adult
  Journal of the American College of Cardiology, 2005
• A small molecule–kinase interaction map for clinical kinase inhibitors
  Nature Biotechnology, 2005
• A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease
  Blood, 2005
• The receptor tyrosine kinase inhibitor SU11248 impedes endothelial cell migration, tubule formation, and blood vessel formation in vivo, but has little effect on existing tumor vessels
  Angiogenesis, 2004